Cardiovascular Outcomes with Sacubitril-Valsartan in Heart Failure: Emerging Clinical Data
Joseph J Cuthbert,1 Pierpaolo Pellicori,2 Andrew L Clark1 1Department of Academic Cardiology, Hull York Medical School, Hull and East Yorkshire Medical Research and Teaching Centre, Castle Hill Hospital, Kingston upon Hull HU16 5JQ, UK; 2Robertson Institute of Biostatistics and Clinical Trials Unit,...
Guardado en:
Autores principales: | Cuthbert JJ, Pellicori P, Clark AL |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f8ba4bb6b9594b65945321b7181eeeb2 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Use of angiotensin receptor – neprilysin inhibitors in heart failure: a paradigm shift
por: M. O.E. Irhuma, et al.
Publicado: (2016) -
Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review
por: Domingo Pascual-Figal, et al.
Publicado: (2021) -
Benefits and adverse effects of sacubitril/valsartan in patients with chronic heart failure: A systematic review and meta‐analysis
por: Elodie Charuel, et al.
Publicado: (2021) -
Efecto antihipertensivo del valsartán: Estudio multicéntrico nacional
por: Prat M.,Hernán
Publicado: (2000) -
Recent and Upcoming Drug Therapies for Pediatric Heart Failure
por: Karla L. Loss, et al.
Publicado: (2021)